This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Humana (HUM) Tops Q4 Earnings & Revenues, Issues '18 View
by Zacks Equity Research
Humana's (HUM) solid fourth-quarter results were driven by strong performance of Retail and Group & Specialty segments.
Humana???s (HUM) Q4 Earnings Surpass Expectations
by Anupama Mukhopadhyay
Humana's fourth quarter operating earnings of $2.06 per share surpassed the Zacks Consensus Estimate of $2.00.
Can Solid Retail Segment Drive Humana's (HUM) Q4 Earnings?
by Zacks Equity Research
Humana's (HUM) fourth-quarter results are likely to gain from solid premium growth, especially in the Retail segment.
Zacks Industry Outlook Highlights: Aetna, Humana, Cigna and Anthem
by Zacks Equity Research
Zacks Industry Outlook Highlights: Aetna, Humana, Cigna and Anthem
Zacks Industry Outlook Highlights: UnitedHealth, Humana, Cigna, Anthem and Centene
by Zacks Equity Research
Zacks Industry Outlook Highlights: UnitedHealth, Humana, Cigna, Anthem and Centene
Disruptive Forces to Keep Health Insurers on Their Toes
by Zacks Equity Research
The year 2018 should be lined with continued policy changes and ongoing uncertainty for health insurers.
Zacks.com highlights: NETGEAR, Marathon Petroleum, Target, Humana and Hudbay Minerals
by Zacks Equity Research
Zacks.com highlights: NETGEAR, Marathon Petroleum, Target, Humana and Hudbay Minerals
CVS Health Grows in PBM With Rheumatoid Arthritis Program
by Zacks Equity Research
The new Transform Rheumatoid Arthritis Care program to help CVS Health (CVS) provide a personalized whole-patient support through specialty pharmacy and embedded AccordantCare nurses.
5 Stocks Riding High on Stellar Relative Price Strength
by Nilanjan Choudhury
Want to try an out-of-the-box approach to earn handsome returns? Tap these stocks with explosive relative price strength.
BD's CE Mark and Check-Point's Screening Test to Fight CPO
by Zacks Equity Research
BD (BDX)-Check-Points' advanced bacterial screening assay will help lower mortality rates caused by AMR.
4 Great Healthcare Stocks to Buy Ahead of Q4 Earnings
by Swarup Gupta
An ageing population and steady demand for healthcare services continue to make stocks from the sector a lucrative option.
UnitedHealth (UNH) Beats on Q4 Earnings, Revises 2018 View
by Zacks Equity Research
UnitedHealth (UNH) Q4 earnings reflect broad-based growth across both its segments.
Higher Optum Revenues to Drive UnitedHealth (UNH) Q4 Earnings
by Zacks Equity Research
Increased contribution across Optum's segments should support UnitedHealth's (UNH) earnings in Q4.
Top Research Reports for Wal-Mart, 3M & Union Pacific
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Wal-Mart (WMT), 3M (MMM) and Union Pacific (UNP).
Humana Extends Contract With Tivity Health, Spurs Healthcare
by Zacks Equity Research
Humana (HUM) continues to form strategic partnerships to improve the overall health of its Medicare Advantage members.
The Zacks Analyst Blog Highlights: Anthem, Humana, Centene, Molina Healthcare and Joint
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Anthem, Humana, Centene, Molina Healthcare and Joint
3 Outperformers from Health Insurance in 2017
by Zacks Equity Research
The health insurance industry has witnessed regulatory uncertainties around Affordable Care Act, public exchange losses and inorganic growth in 2017.
Can Walgreens' Retail Pharmacy USA Segment Drive Q1 Earnings?
by Zacks Equity Research
Walgreens Boots (WBA) rides high on strength in Retail Pharmacy USA division in fiscal 2017.
Anthem Buys HealthSun to Expand Medicare Business in Florida
by Zacks Equity Research
Anthem's (ANTM) buyout of HealthSun reflects its long-term strategy to grow in the Medicare Advantage business.
Humana-Kindred Deal Keeps Shakeout Alive in Healthcare Space
by Zacks Equity Research
Humana's (HUM) agreement to acquire Kindred at Home aligns with its strategy to grow vertically.
PBM Industry Shows Strength: 3 Stocks in Focus
by Zacks Equity Research
Consider these three stocks for grand returns from the high-potential PBM market.
CVS-Aetna Deal: What's Hot, What's Not
by Zacks Equity Research
CVS Health (CVS) and Aetna consolidation to add a new dimension to healthcare landscape. However, critics believe the gain will be short-lived for the healthcare society.
Humana Partners Einstein Healthcare for Value-Based Care
by Zacks Equity Research
Humana (HUM) has been joining forces with other medical sector companies in order to strengthen its presence in value-based healthcare.
Humana's Medicare Business Impresses, Public Exchange Hurts
by Zacks Equity Research
Although Humana (HUM) continues to grow on the back of Medicare and Medicaid expansions, threats from its exchange business weigh on both revenues and margins.
Can Health Insurers Continue to Look Past ACA Threats in Q4?
by Zacks Equity Research
Despite regulatory challenges, health insurance companies have the potential to outperform in Q4 on growing demand for government plans, reduced uninsured rates and aging U.S. population.